May 2018 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2016/17 Invitation to Tender, dated 3 November 2016 and the 2017/18 Invitation to Tender, dated 2 November 2017.
Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (http://www.pgnz.org.nz/about-us-1/pharmacode(external link)) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (http://www.nzulm.org.nz/sponsors(external link)). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2016/17 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2020
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
1. Tenders awarded to pharmaceuticals where no brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Pack Price | Hospital Supply Brand (Supplier) |
DVLimit | Listing date | Hospital Supply Status date |
|---|---|---|---|---|---|---|
| Granisetron | Inj 1 mg per ml, 3 ml ampoule, 1 ampoule | $0.40 | Deva (Deva Holdings) |
1% | 1 September 2018 | 1 November 2018 |
2017/18 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2021
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
2. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current subsidy (and price) | New subsidy (and price) | Sole supply brand (Supplier) | Date of subsidy change | Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
| Candesartan cilexetil* | Tab 4 mg, 90 tablet bottle pack | $2.50 | $1.90 | Candestar (Mylan) |
1 July 2018 | 1 October 2018 |
| Candesartan cilexetil* | Tab 8 mg, 90 tablet bottle pack | $3.68 | $2.28 | Candestar (Mylan) |
1 July 2018 | 1 October 2018 |
| Candesartan cilexetil* | Tab 16 mg, 90 tablet bottle pack | $6.12 | $3.67 | Candestar (Mylan) |
1 July 2018 | 1 October 2018 |
| Candesartan cilexetil* | Tab 32 mg, 90 tablet bottle pack | $10.66 | $6.39 | Candestar (Mylan) |
1 July 2018 | 1 October 2018 |
| Ciclopirox olamine | Nail-soln 8%, 7 ml bottle OP | $6.50 | $5.72 | Apo-Ciclopirox (Apotex) |
1 July 2018 | 1 October 2018 |
| Heparin sodium | Inj 5,000 iu per ml, 5 ml ampoule, 50 plastic ampoules | $341.89 | $203.68 | Pfizer (Pfizer New Zealand Ltd) |
1 September 2018 | 1 December 2018 |
| Oil in water emulsion | Crm, 500 g tub | $2.25 | $2.19 | O/W Fatty Emulsion Cream (Boucher and Muir (NZ) Limited) |
1 November 2018 | 1 February 2019 |
| *Special Authority restriction applying to candesartan cilexetil will be removed from 1 July 2018 | ||||||
3. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current subsidy (and price) | New subsidy (and price) | Sole supply brand (Supplier) | Date of listing/subsidy change for tender winning brand | Date of reference pricing of other listed brands | Sole Subsidised Supply date (and delisting of other listed brands) | Brand (Supplier) affected by reference pricing and delisting |
|---|---|---|---|---|---|---|---|---|
| Heparin sodium | Inj 1,000 iu per ml, 5 ml ampoule, 50 plastic ampoules | $99.50 | $58.57 | Pfizer (Pfizer New Zealand Ltd) |
1 September 2018 | 1 November 2018 | 1 February 2019 | Hospira (Pfizer New Zealand Ltd)10 inj and 50 inj packs |
| Ibuprofen | Oral liq 20 mg per ml, 200 ml bottle | $2.39 | $1.88 | Ethics (Multichem New Zealand Ltd) |
1 March 2019 | 1 May 2019 | 1 August 2019 | Fenpaed (AFT) |
| Metformin hydrochloride | Tab immediate-release 500 mg, 1,000 tablet bottle pack | $9.59 | $8.63 | Apotex (Apotex NZ Ltd) |
1 December 2018 | 1 February 2019 | 1 May 2019 | Metchek (API) |
| Metformin hydrochloride | Tab immediate-release 850 mg, 500 tablet bottle pack | $7.82 | $7.04 | Apotex (Apotex NZ Ltd) |
1 December 2018 | 1 February 2019 | 1 May 2019 | Metformin Mylan (Mylan) |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
CORRECTION to May 2018 tender notification: in bold and strikethrough
4. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
| Chemical Name | Presentation; Pack size and type |
Current price | New price | Hospital Supply Brand (Supplier) | DVLimit | Listing date | Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
| Candesartan cilexetil* | Tab 4 mg, 90 tablet bottle pack | $2.50 | $1.90 | Candestar (Mylan) |
1% | 1 July 2018 | 1 September 2018 |
| Candesartan cilexetil* | Tab 8 mg, 90 tablet bottle pack | $3.68 | $2.28 | Candestar (Mylan) |
1% | 1 July 2018 | 1 September 2018 |
| Candesartan cilexetil* | Tab 16 mg, 90 tablet bottle pack | $6.12 | $3.67 | Candestar (Mylan) |
1% | 1 July 2018 | 1 September 2018 |
| Candesartan cilexetil* | Tab 32 mg, 90 tablet bottle pack | $10.66 | $6.39 | Candestar (Mylan) |
1% | 1 July 2018 | 1 September 2018 |
| Ciclopirox olamine | Nail soln 8%, 7 ml bottle (OP) | $6.50 | $5.72 | Apo-Ciclopirox (Apotex) |
1% | 1 July 2018 | 1 September 2018 |
| Heparin sodium | Inj 1,000 iu per ml, 5 ml ampoule, 50 plastic ampoules | $99.50 | $58.57 | Pfizer (Pfizer New Zealand Ltd) |
1% | 1 September 2018 | 1 November 2018 |
| Heparin sodium | Inj 5,000 iu per ml, 5 ml ampoule, 50 plastic ampoules | $341.89 | $203.68 | Pfizer (Pfizer New Zealand Ltd) |
1% | 1 September 2018 | 1 November 2018 |
| Oil in water emulsion | Crm, 100 g tub | $1.60 | $1.44 | healthE Fatty Cream (Jaychem) |
1% | 1 October 2018 | 1 December 2018 |
| Tropisetron | Inj 1 mg per ml, 2 ml ampoule, 1 ampoule | $8.95 | $8.95 | Tropisetron-AFT (AFT) |
1% | 1 July 2018 | 1 September 2018 |
| *Indication Restriction applying to candesartan cilexetil will be removed from 1 July 2018 | |||||||
5. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
| Chemical Name | Presentation; Pack size and type |
Current price | New price | Hospital Supply Brand (Supplier) | DVLimit | Listing date | Hospital Supply Status date | Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
| Ibuprofen | Oral liq 20 mg per ml, 200 ml bottle | $2.39 | $1.88 | Ethics (Multichem New Zealand Ltd) |
1% | 1 March 2019 | 1 May 2019 | Fenpaed(AFT) |
| Metformin hydrochloride | Tab immediate-release 500 mg, 1,000 tablet bottle pack | $9.59 | $8.63 | Apotex (Apotex NZ Ltd) |
1% | 1 December 2018 |
1 February 2019 | Metchek(API) |
| Metformin hydrochloride | Tab immediate-release 850 mg, 500 tablet bottle pack | $7.82 | $7.04 | Apotex (Apotex NZ Ltd) |
1% | 1 December 2018 |
1 February 2019 | Metformin Mylan(Mylan) |
| Midazolam | Inj 1 mg per ml, 5 ml ampoule, 10 glass ampoules | $4.30 | $2.98 | Mylan Midazolam (Mylan New Zealand Ltd) |
1% | 1 November 2018 | 1 January 2019 | Midazolam-Claris(AFT) |
| Midazolam | Inj 5 mg per ml, 3 ml ampoule, 5 glass ampoules | $2.50 | $2.36 | Mylan Midazolam (Mylan New Zealand Ltd) |
1% | 1 November 2018 | 1 January 2019 | Midazolam-Claris(AFT) |
| Oil in water emulsion1 | Crm, 500 g, tub | $2.63 | $2.19 | O/W Fatty Emulsion Cream (Boucher and Muir (NZ) Limited) |
1% | 1 November 2018 | 1 January 2019 | healthE Fatty Cream(Jaychem) |
| Sodium chloride | Inj 0.9%, 3 ml syringe, non-sterile pack, 480 prefilled syringes2 | $10.65 per 30 | $160.90 | BD PosiFlush (Becton Dickinson) |
1% | 1 July 2018 | 1 September 2018 | BD PosiFlush(30 pack) |
| Sodium chloride | Inj 0.9%, 5 ml syringe, non-sterile pack, 480 prefilled syringes2 | $10.80 per 30 | $162.91 | BD PosiFlush (Becton Dickinson) |
1% | 1 July 2018 | 1 September 2018 | BD PosiFlush(30 pack) |
| Sodium chloride | Inj 0.9%, 10 ml syringe, non-sterile pack, 480 prefilled syringes2 | $11.25 per 30 | $170.35 | BD PosiFlush (Becton Dickinson) |
1% | 1 July 2018 | 1 September 2018 | BD PosiFlush(30 pack) |
| 1Note: DV limit applies to pack size greater than 100 g. 2The pack size for BD PosiFlush sodium chloride syringes is 480 which is an outer carton containing 16 x 30 syringe shelf packs. |
||||||||
Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2016/17 Invitation to Tender, dated 3 November 2016, and the 2017/18 Invitation to Tender, dated 2 November 2017:
2016/17 Invitation to Tender
| Chemical Name | Line Item | Chemical Name | Line Item |
|---|---|---|---|
| Tetracaine [amethocaine] hydrochloride | Gel 4% | Trimethoprim with sulphamethoxazole [Co-trimoxazole] | Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml |
2017/18 Invitation to Tender
| Chemical Name | Line Item |
|---|---|
| Adefovir dipivoxil | Tab 10 mg |
| Amoxicillin clavulanate | Inj 500 mg with clavulanic acid 100 mg |
| Amoxicillin clavulanate | Inj 1000 mg with clavulanic acid 200 mg |
| Beractant | Inj 25 mg per ml, 8 ml |
| Calcium carbonate | Tab eff 0.875 – 1.75 g (0.5 g – 1 g elemental) |
| Calcium carbonate | Oral liq 250 mg per ml (100 mg elemental per ml) |
| Candesartan (current access) | Tab 4 mg |
| Candesartan (current access) | Tab 8 mg |
| Candesartan (current access) | Tab 16 mg |
| Candesartan (current access) | Tab 32 mg |
| Carmustine | Inj 100 mg |
| Cidofovir | Inj 75 mg per ml, 5 ml |
| Colestimethate | Inj 150 mg |
| Dextrochlorpheniramine maleate | Tab 2 mg |
| Dextrochlorpheniramine maleate | Oral liq 2 mg per 5 ml |
| Econazole nitrate | Crm 1% |
| Etidronate disodium | Tab 200 mg |
| Etoposide | Inj 20 mg per ml, 5 ml |
| Fexofenadine hydrochloride | Tab 60 mg |
| Framycetin sulphate | Ear/eye drops 0.5% |
| Gentamicin sulphate | Inj 10 mg per ml |
| Glucose [dextrose] | Gel 40% |
| Glyceryl trinitrate | Inj 5 mg per ml, 10 ml |
| Hydrocortisone | Oint 1% (pack size greater than 100 g) |
| Hydrocortisone | Oint 1% (pack size 100 g or less) |
| Hydrocortisone | Oral liq |
| Hydrocortisone | Tab 1 mg |
| Intra-uterine device | IUD 29.1 mm length x 23.2 mm width |
| Intra-uterine device | IUD 33.6 mm length x 29.9 mm width |
| Intra-uterine device | IUD 35.5 mm length x 19.6 mm width |
| Lodoxamide | Eye drops 0.1% |
| Mefloquine hydrochloride | Tab 250 mg |
| Metformin hydrochloride | Tab immediate-release 1 g |
| Methadone hydrochloride | Inj 10 mg per ml, 1 ml |
| Metronidazole | Gel 0.75% |
| Metronidazole | Oral liq benzoate 200 mg per 5 ml |
| Metronidazole | Suppos 500 mcg |
| Metronidazole | Tab 200 mg |
| Metronidazole | Tab 400 mg |
| Noradrenaline | Inj 0.06 mg per ml, 100 ml bag |
| Noradrenaline | Inj 0.12 mg per ml, 100 ml bag |
| Noradrenaline | Inj 0.16 mg per ml, 50 ml syringe |
| Phenytoin | Inj 50 mg per ml, 2 ml |
| Phenytoin | Inj 50 mg per ml, 5 ml |
| Poractant alfa | Soln 120 mg per 1.5 ml vial |
| Poractant alfa | Soln 240 mg per 3 ml vial |
| Potassium dihydrogen phosphate | Inj 1 mmol per ml, 10 ml |
| Povidone iodine | Skin preparation, povidone iodine 10% with 20% alcohol (pack size greater than 100 ml) |
| Ticarcillin with clavulanic acid | Inj 3 g with clavulanic acid 0.1 mg vial |
| Tropisetron | Inj 1 mg per ml, 5 ml |
| Zopiclone | Tab 3.75 |
For products included in the 2015/16, 2016/17 and 2017/18 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.